Encouraging signs for 2020, despite continued lag in the medical device industry in Q4

Fourth quarter 2019

• Net sales amounted to 60.2 (65.2) MSEK.
• Operating result for the period before depreciations (EBITDA) totaled  11.8 (24.3) MSEK.
• Net result for the period amounted to 7.8 (27.8) MSEK.
• Earnings per share (EPS) was 0.32 (2.48) SEK.
• Order intake amounted to 54.7 (61.9) MSEK.
• The order book was 39.8 (50.1) MSEK.
• Cash flow from operating activities totalled -17.4 (12.4) MSEK.

January-December 2019

• Net sales amounted to 149.4 (157.0) MSEK.
• Operating result for the period before depreciations (EBITDA) totaled -12.9 (20.8) MSEK.
• Net result for the period amounted to -20.6 (20.1) MSEK.
• Earnings per share (EPS) was -1.05 (1.80) SEK.
• Order intake amounted to 139.1 (174.3) MSEK.
• The order book was 39.8 (50.1) MSEK.
• Cash flow from operating activities totalled -38.0 (16.0) MSEK.

“After the fourth quarter of 2019, we are 7.6 % below in net sales compared to same period last year and 11.6 % below on orders received. As stated in the Q3 report, a major cause of this lag is orders being pushed forward and we continued to experience this in Q4 where multiple orders were being pushed into 2020. Our start to the first quarter is ahead of last year both from a net sales and order point of view and we see relevant progress on the delayed deals from last year,” says Göran Malmberg, CEO of Mentice AB (publ).

Webcast presentation of the year-end report

Mentice's year-end report for January–December 2019 will be presented by CEO Göran Malmberg with the possibility to ask questions on February 27, 2020 at 10:00 CET. The presentation will be held via the web and in English.

To register for the presentation, please visit www.mentice.com/financial-reports-presentations Please make sure to register at least a few minutes in advance.

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on February 27, 2020 08:30 CET.  

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.